Treating cardiac amyloidosis in heart failure with preserved ejection
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This trial studies people with heart failure with preserved ejection fraction (HFpEF) and cardiac amyloidosis (an abnormal protein buildup in the heart). It may help researchers understand better treatment for symptoms and heart function in this group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 60 or older (or age 50 with carpal tunnel syndrome or spinal stenosis)
- You have been diagnosed with HFpEF (heart failure where pumping strength is preserved) or are being newly diagnosed
- You have heart failure symptoms and a functional status that ranges from NYHA Class I to IV
- Your heart ultrasound shows a left ventricular posterior wall thickness (LVPW) of at least 12 mm in more than half of your measurements at diagnosis
- You are able and willing to sign informed consent to join the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study enrolls patients suspected of having or recently diagnosed with cardiac amyloidosis—a condition where abnormal protein deposits thicken the heart muscle. Researchers will use imaging tests like echocardiography and MRI to better understand the disease and track how it changes over time, which may improve future treatment options.
This study looks at how the heart muscle works in people with a type of heart failure where the heart pumps normally but doesn't fill properly. It aims to understand the cause better, which could lead to new treatments.
This study is testing better ways to understand and manage heart failure where the heart pumps normally but still doesn't work as well as it should. It looks at people with symptoms like shortness of breath and fatigue, using blood tests and heart imaging to check eligibility.
This trial studies whether ultrasound therapy can help people with amyloidosis that affects the heart. It’s aimed at improving heart-related outcomes in AL or transthyretin (ATTR) cardiac amyloidosis.
This study tests whether a 12-week supervised exercise program is safe and helpful for people with cardiac amyloidosis and heart failure. It aims to see if regular exercise can improve how you feel and function.
This trial is testing older adults with heart failure to see if a heart condition called cardiac amyloidosis (a buildup of abnormal protein in the heart) is present. If you are 80 or older, have been in the hospital for heart failure in the past year, and have a thickened heart wall, you may be able to join.
Hear when a new Heart Failure With Preserved Ejection Fraction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.